Abstract:Invasive fungal infections (IFI) are an emerging problem worldwide with invasive candidiasis and candidemia responsible for the majority of cases. This is predominantly driven by the widespread adoption of aggressive immunosuppressive therapy among certain patient populations (e.g., chemotherapy, transplants) and the increasing use of invasive devices such as central venous catheters (CVCs). The use of new immune modifying drugs has also opened up an entirely new spectrum of patients at risk of IFIs. While the epidemiology of candida infections has changed in the last decade, with a gradual shift from C. albicans to non-albicans candida (NAC) strains which may be less susceptible to azoles, these changes vary between hospitals and regions depending on the type of population risk factors and antifungal use. In certain parts of the world, the incidence of IFI is strongly linked to the prevalence of other disease conditions and the ecological niche for the organism; for instance cryptococcal and pneumocystis infections are particularly common in areas with a high prevalence of HIV disease. Poorly controlled diabetes is a major risk factor for invasive mould infections. Environmental factors and trauma also play a unique role in the epidemiology of mould infections, with well-described hospital outbreaks linked to the use of contaminated instruments and devices. Blastomycosis is associated with occupational exposure (e.g., forest rangers) and recreational activities (e.g., camping and fishing).The true burden of IFI is probably an underestimate because of the absence of reliable diagnostics and lack of universal application. For example, the sensitivity of most blood culture systems for detecting candida is typically 50 %. The advent of new technology including molecular techniques such as 18S ribosomal RNA PCR and genome sequencing is leading to an improved understanding of the epidemiology of the less common mould and dimorphic fungal infections. Molecular techniques are also providing a platform for improved diagnosis and management of IFI.Many factors affect mortality in IFI, not least the underlying medical condition, choice of therapy, and the ability to achieve early source control. For instance, mortality due to pneumocystis pneumonia in HIV-seronegative individuals is now higher than in seropositive patients. Of significant concern is the progressive increase in resistance to azoles and echinocandins among candida isolates, which appears to worsen the already significant mortality associated with invasive candidiasis. Mortality with mould infections approaches 50 % in most studies and varies depending on the site, underlying disease and the use of antifungal agents such as echinocandins and voriconazole. Nevertheless, mortality for most IFIs has generally fallen with advances in medical technology, improved care of CVCs, improved diagnostics, and more effective preemptive therapy and prophylaxis.

The epidemiology of invasive candidiasis in China

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Clinical analysis of 14 cases of candidemia

Invasive Candidiasis in Intensive Care Units in China: a Multicentre Prospective Observational Study

The Species Distribution of Candidemia and the Advances on Diagnosis and Treatment

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

A Ten-year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital in Beijing.

Invasive Candidiasis in Intensive Care Units in China: Risk Factors and Prognoses of Candida Albicans and Non-Albicans Candida Infections

Comparative Analysis of Epidemiological and Clinical Characteristics Between Invasive Candida Infection Versus Colonization in Critically Ill Patients in a Tertiary Hospital in Anhui, China

A Ten-Year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital

Epidemiology, Clinical Characteristics, and Risk Factors for Mortality of Early- and Late-Onset Invasive Candidiasis in Intensive Care Units in China.

Epidemiological study of invasive nosocomial candidiasis in 2 teaching hospitals in Beijing]

Candidaemia: A 9-Year Retrospective Analysis of Epidemiology and Antimicrobial Susceptibility in Tertiary Care Hospitals in Western China

Emerging trends of invasive yeast infections and azole resistance in Beijing intensive care units

Molecular Epidemiology, Antifungal Susceptibility, and Virulence Evaluation of Candida Isolates Causing Invasive Infection in a Tertiary Care Teaching Hospital

Epidemiology of Invasive Candidiasis

Pathogen Distribution and Drug Resistance in A Burn Ward: A Three-Year Retrospective Analysis of A Single Center in China

Epidemiology, Species Distribution, Antifungal Susceptibility and Mortality Risk Factors of Candidemia among Critically Ill Patients: a Retrospective Study from 2011 to 2017 in a Teaching Hospital in China

Clinical Features and Prognostic Risk Factors of Candidemia in Non-Intensive Care Unit Wards

Molecular Epidemiology and Antifungal Susceptibility of Candida Glabrata in China (august 2009 to July 2014): A Multi-Center Study.

The Changing Epidemiology of Invasive Fungal Infections